Skip to main content

Table 1 Baseline characteristics of all PMN patients and subgroups classified into ET, PMF and PV syndrome

From: Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms

Clinical characteristics PMN (n = 105) ET (n = 67) PV (n = 16) PMF (n = 22) P a
Gender - male (%) 77 (73.3) 50 (74) 10 (62.5) 17 (77.3) NS
Age (years) 64 (16–96) 64 (16–96) 69 (29–86) 57 (29–85) NS
WBC (× 103/mL) 14.3 (1.9–87.2) 14.8 (6.8–66.5) 8.2 (5.2–31.9) 15.5 (1.9–87.2) 0.039
RBC (× 106/mL) 4.8 (2.1–9.7) 4.5 (2.5–8.1) 5.7 (5.4–9.7) 4.5 (2.14–9.7) 0.0002
PLT(×103/mL) 710 (45–2301) 820 (376–2301) 233 (150–803) 246 (45–1776) 6.15e-11
Hb (g/L) 138 (10.5–211) 132 (10.5–188) 185 (167–211) 125 (66–178) 2.17e-08
  1. Abbreviation: Hb, hemoglobin; PLT, platelets; WBC, white blood cell; RBC, red blood cell; NS, not significant. Values given are medians and range. (a) in comparison between subgroups (ET, PV and PMF). P values were calculated by Chi-squared and Kruskal-Wallis test where appropriate